mTOR was positively correlated with an improved OS in female patients with ccRCC [HR 95% CI = 0.27 (0.14–0.52)], whereas AKT2 was positively correlated with poor OS in males [HR 95% CI = 1.71 (1.15–2.55)]. This evidence concerns the gene AKT2 and nonpapillary renal cell carcinoma.